Anzeige
Mehr »
Login
Samstag, 14.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Der nächste MicroStrategy? Der Solana-Schachzug dieses Unternehmens ist UMWERFEND
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
392 Leser
Artikel bewerten:
(2)

Biosimilars Market Size to Reach USD 22550 Million by 2028 at CAGR 15.0% - Valuates Reports

Finanznachrichten News

BANGALORE, India, March 17, 2022 /PRNewswire/ -- The Biosimilars Market is Segmented by Type (Human Growth Hormones, Monoclonal Antibodies, Insulin, Peptides, Erythropoietin, Others), and Application (Oncology, Chronic and Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Others). The report covers global opportunity analysis, regional outlook, growth potential, industry forecast from 2022 to 2028.

Valuates Reports Logo

The Biosimilar market was valued at USD 9752.7 Million in 2022, and it is anticipated to reach USD 22550 Million by 2028, registering a CAGR of about 15.0% during the forecast period (2022-2028).

Major Factors Driving The Growth Of The Biosimilars Market

The increasing prevalence of chronic diseases such as cancer, autoimmune disorders, and the rising geriatric population has increased the demand for biosimilars. The reduced development costs, quick time to market delivery and rising healthcare expenditure create lucrative opportunities for the global biosimilar market. Quality and affordable treatment options enhance patient care and lead to cost savings and efficiencies in the healthcare system.

The gradual patent expiry of several blockbuster biologic drugs will create immense opportunities for biosimilar manufacturers in the upcoming years.

Moreover, the increasing research and development initiatives for developing monoclonal antibodies will significantly boost the biosimilar market growth during the forecast period.

Get your sample today: https://reports.valuates.com/request/sample/QYRE-Othe-0T469/Biosimilar_Market

Trends Influencing The Growth Of The Biosimilar Market

The growing number of chronic diseases, autoimmune disorders, cancer and rising geriatric population has positively impacted the biosimilar market trends. These drugs provide quality, low cost health care services to a wide number of patients. The quick time to market delivery and reduced development costs enables companies to launch biosimilars faster into the market. This reduces healthcare expenditure, increases efficiency and provides more therapeutic options to patients. The better health outcomes will ultimately drive the global biosimilar market during the forecast period.

A huge number of blockbuster branded biologic drugs are facing patent expiry in the coming years. This will create a severe shortage of drugs for filling the gap required for treatment of diseases. Hence government authorities and third party payers are encouraging the use of biosimilars. This will create huge scope for the growth of the biosimilar market in the future.

The increasing research and development initiatives for developing mAbs(Monoclonal Antibodies) has already reached the stages of clinical trials. These antibodies are aimed at combating cancer, autoimmune or inflammatory diseases. A variety of mAbs are being developed that show great promise in the field of biosimilars. This will create ample opportunities for market growth during the forecast period.

Browse the Table of Contents and List of figures at: https://reports.valuates.com/reports/QYRE-Othe-0T469/biosimilar

Biosimilar Market Share Analysis

Based on product, the monoclonal antibodies segment is expected to dominate in the biosimilar market share due to potential benefits of low cost healthcare expense and widespread application in treatment of diseases such as cancer, autoimmune disorders etc.

Based on application, Oncology is the largest in the biosimilar market share due to the growing number of cancer cases globally. Biosimilars are an affordable alternative for reducing the costly cancer treatment options.

Based on region, North America is expected to provide lucrative opportunities for growth in the biosimilar market share due to increasing prevalence of diseases and rising R&D initiatives by key players.

Report Customization Request: https://reports.valuates.com/request/customisation/QYRE-Othe-0T469/Biosimilar_Market

This report includes the following companies; we can also add the other companies as you want.

  • Allergan plc
  • BIOCAD
  • Biocon
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Celltrion
  • Coherus BioSciences
  • Dr. Reddy's Laboratories
  • Genor BioPharma
  • Intas Pharmaceuticals Limited
  • Novartis
  • Pfizer
  • Others Players

Chapter Cost Request: https://reports.valuates.com/request/chaptercost/QYRE-Othe-0T469/Biosimilar_Market

Buy Now for Single User + Covid-19 Impact: https://reports.valuates.com/api/directpaytoken?rcode=QYRE-Othe-0T469&lic=single-user

SUBSCRIPTION

We have introduced a tailor-made subscription for our customers. Please leave a note in the Comment Section to know about our subscription plans.

SIMILAR REPORTS

  • The ASEAN and China biosimilars market was valued at USD 687.6 Million in 2017 and is expected to reach USD 5,506.2 Million by 2025 with a CAGR of 29.7% during the forecast period.
  • The global Biosimilar Monoclonal Antibodies market size is estimated to be worth USD 5320.8 Million in 2022 and is forecast to a readjusted size of USD 12960 Million by 2028 with a CAGR of 16.0% during the review period.
  • The global Biopharmaceuticals market was valued at USD 82330 Million in 2020 and is projected to reach USD 113300 Million by 2027, registering a CAGR of 4.7% from 2021 to 2027.
  • The global Biologics and Biosimilars market was valued at USD 182380 Million in 2020 and is expected to reach USD 260090 Million by the end of 2027, growing at a CAGR of 5.1% during 2021-2027.
  • The global biomaterials market size was valued at USD 64874 Million in 2020 and is expected to reach USD 212405.2 Million by 2030 growing at a CAGR of 12.7% from 2021 to 2030.
  • Global Oncology Biosimilars Market Insights and Forecast to 2028
  • Global Biosimilar Drug Market Insights and Forecast to 2028
  • Global Bevacizumab Biosimilar Market Insights and Forecast to 2028
  • Global Interferon Biosimilar Market Insights and Forecast to 2028
  • Cell Culture Market Size, Forecasts 2020 to 2027
  • Global Recombinant Non-Glycosylated Proteins Biosimilars Market Insights and Forecast to 2028

To see the full list of related reports on the Biosimilars

ABOUT US:

Valuates offers in-depth market insights into various industries. Our extensive report repository is constantly updated to meet your changing industry analysis needs.

Our team of market analysts can help you select the best report covering your industry. We understand your niche region-specific requirements and that's why we offer customization of reports. With our customization in place, you can request for any particular information from a report that meets your market analysis needs.

To achieve a consistent view of the market, data is gathered from various primary and secondary sources, at each step, data triangulation methodologies are applied to reduce deviance and find a consistent view of the market. Each sample we share contains detail research methodology employed to generate the report, Please also reach to our sales team to get the complete list of our data sources

CONTACT US:

Valuates Reports
sales@valuates.com
For U.S. Toll-Free Call +1-(315)-215-3225
For IST Call +91-8040957137
WhatsApp: +91 9945648335
Website: https://reports.valuates.com
Follow on Twitter - https://twitter.com/valuatesreports
Follow on Linkedin - https://in.linkedin.com/company/valuatesreports
Follow on Facebook - https://www.facebook.com/valuatesreports

Logo: https://mma.prnewswire.com/media/1082232/Valuates_Reports_Logo.jpg

© 2022 PR Newswire
5 heiße Wetten für den Jahresendspurt!
Nach dem unerwartet schnellen Ende der US-Wahlen mit dem Sieg des republikanischen Kandidaten Donald Trump fackelten die Aktien- und Krypto- Märkte ein wahres Kursfeuerwerk ab und bliesen zur Jahresendrallye.

Im aktuellen kostenlosen Report beleuchten wir 5 aussichtsreiche Unternehmen, die das Fundament besitzen, in den nächsten Monaten den breiten Markt zu schlagen.

Seien Sie dabei!

Fordern Sie jetzt unseren brandneuen neuen Spezialreport an und erfahren Sie, welche Aktien aufgrund ihrer Bewertung sowie charttechnischen Situation das Potenzial zu einer Outperformance besitzen.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.